Market Overview

UPDATE: Piper Jaffray Cuts PT to $15 on Achillion Pharmaceuticals on Equity Offering Dilution

Related ACHN
Achillion Announces Janssen Initiated Phase 2a Study to Evaluate Combination of AL-335, ACH-3102, and Simeprevir for Treatment of Genotype 1 Chronic HCV
UBS: Biotech Will Continue To Outperform In 2015

Piper Jaffray maintained Achillion Pharmaceuticals (NASDAQ: ACHN) with an Overweight rating and lowered the price target from $16.00 to $15.00.

Piper Jaffray said, "Achillion now holds proforma cash of $211 million following a recent 16.9 million share offering. We are buyers of ACHN shares ahead of SVR-4 data from the 12-week trial of ACH-3102 + ribavarin in 8 HCV genotype 1b patients at EASL in April. … We continue to see Achillion as a likely take-out candidate for its promising HCV pipeline. We reiterate our Overweight rating, however are trimming our price target to $15 from $16 price target due to dilution from the equity offering."

Achillion Pharmaceuticals closed at $8.15 on Friday.

Latest Ratings for ACHN

Oct 2015JefferiesMaintainsHold
Sep 2015JefferiesInitiates Coverage onHold
Sep 2015UBSUpgradesNeutralBuy

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (ACHN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters